12−month TUD−related outcomes in patients with obesity and TUD (no T2D)
(comparison between propensity−score matched cohorts: semaglutide vs smoking cessation medications)

Outcome	Semaglutide cohort # of cases (overall risk)	Smoking cessation medications cohort # of cases (overall risk)		HR (95% CI)
Semaglutide vs Nicotine replacement therapy (n=1,131/cohort)				
Medical encounter for TUD diagnosis	540 (47.7%)	691 (61.1%)		0.62 (0.56−0.70)
Smoking cessation counseling	70 (6.2%)	102 (9.0%)		0.66 (0.49−0.90)
Nicotine replacement therapy	107 (9.5%)	534 (47.2%)		0.15 (0.12−0.19)
Prescription of quit−smoking medications	189 (16.7%)	212 (18.7%)		0.85 (0.70−1.04)
Semaglutide vs Bupropion/Varenicline (n=1,173/cohort)				
Medical encounter for TUD diagnosis	562 (47.9%)	685 (58.4%)		0.72 (0.64−0.80)
Smoking cessation counseling	71 (6.1%)	102 (8.7%)		0.69 (0.51−0.93)
Nicotine replacement therapy	110 (9.4%)	187 (15.9%)		0.56 (0.45−0.71)
Prescription of quit−smoking medications	202 (17.2%)	609 (51.9%)		0.25 (0.22−0.30)

0.10 0.30 0.90 3.00 9.00

Hazard Ratio (HR)